Cutaneous leishmaniasis

Clinics in Dermatology

Volumn 25, Issue 2, 2007, Pages 203-211

  Bailey, Mark S ^a,b   Lockwood, Diana N J ^c  

^a Army Medical Directorate   (United Kingdom)

^b LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; FLUCONAZOLE; IMIDAZOLE; ITRACONAZOLE; KETOCONAZOLE; MEGLUMINE ANTIMONATE; METHYLBENZETHONIUM CHLORIDE; MILTEFOSINE; NONSTEROID ANTIINFLAMMATORY AGENT; PAROMOMYCIN; PENTAMIDINE; PLACEBO; STIBOGLUCONATE SODIUM; UREA;

AMYLASE BLOOD LEVEL; ARTICLE; BLOOD CELL COUNT; CLINICAL FEATURE; CRYOTHERAPY; CURETTAGE; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; ECG ABNORMALITY; HUMAN; HYPERTHERMIC THERAPY; LABORATORY TEST; LEISHMANIA; MUSCULOSKELETAL DISEASE; PANCREATITIS; PARASITE TRANSMISSION; PRIORITY JOURNAL; PSYCHODIDAE; SIDE EFFECT; SKIN LEISHMANIASIS; SUPERINFECTION; TROPICS;

AMEBICIDES; ANTIFUNGAL AGENTS; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; BENZETHONIUM; CRYOTHERAPY; CURETTAGE; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPERTHERMIA, INDUCED; LEISHMANIASIS, CUTANEOUS; PAROMOMYCIN;

EID: 33847615668     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2006.05.008     Document Type: Article

References (81)

1. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 95 (2001) 239-243
2. Reyburn H., Rowland M., Mohsen M., Khan B., and Davies C. The prolonged epidemic of anthroponotic cutaneous leishmaniasis in Kabul, Afghanistan: 'bringing down the neighbourhood'. Trans R Soc Trop Med Hyg 97 (2003) 170-176
3. Bailey MS, Caddy AJ, McKinnon KA, et al. Zoonotic cutaneous leishmaniasis with local dissemination in Afghanistan. 2007 [in press].
4. Harms G., Schönian G., and Feldmeier H. Leishmaniasis in Germany. Emerg Infect Dis 9 (2003) 872-875
5. Weina P.J., Neafie R.C., Wortmann G., Polhemus M., and Aronson N.E. Old world leishmaniasis: an emerging infection among deployed US military and civilian workers. Clin Infect Dis 39 (2004) 1674-1680
6. Sanchez J.L., Diniega B.M., Small J.W., et al. Epidemiologic investigation of an outbreak of cutaneous leishmaniasis in a defined geographic focus of transmission. Am J Trop Med Hyg 47 (1992) 47-54
7. Reithinger R., Aadil K., Kolaczinski J., Mohsen M., and Hami S. Social impact of leishmaniasis, Afghanistan. Emerg Infect Dis 11 (2005) 634-636
8. Reithinger R., Mohsen M., Wahid M., et al. Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, control trial. Clin Infect Dis 40 (2005) 1148-1155
9. Gradoni L., and Gramiccia M. Leishmania infantum tropism: strain genotype or host immune status?. Parasitol Today 10 (1994) 264-267
10. Karunaweera N.D., Pratlong F., Siriwardane H.V., Ihalamulla R.L., and Dedet J.P. Sri Lankan cutaneous leishmaniasis is caused by Leishmania donovani zymodeme MON-37. Trans R Soc Trop Med Hyg 97 (2003) 380-381
11. Noyes H., Chance M., Ponce C., Ponce E., and Maingon R. Leishmania chagasi: genotypically similar parasites from Honduras cause both visceral and cutaneous leishmaniasis in humans. Exp Parasitol 85 (1997) 264-273
12. Zijlstra E., Musa A., Khalil E., El Hassan I., and El-Hassan A. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis 3 (2003) 87-98
13. Mehregan D.R., Mehregan A.H., and Mehregan D.A. Histological diagnosis of cutaneous leishmaniasis. Clin Dermatol 17 (1999) 297-304
14. Ghersetich I., Menchini G., Teofoli P., and Lotti T. Immune response to Leishmania infection in human skin. Clin Dermatol 17 (1999) 333-338
15. Kubba R., al-Gindan Y., el-Hassan A.M., Omer A.H., Kutty M.K., and Saeed M.B. Dissemination in cutaneous leishmaniasis. II. Satellite papules and subcutaneous induration. Int J Dermatol 27 (1988) 702-706
16. Gaafar A., Fadl A., El Kadaro A.Y., et al. Sporotrichoid cutaneous leishmaniasis due to Leishmania major of different zymodemes in the Sudan and Saudi Arabia: a comparative study. Trans R Soc Trop Med Hyg 88 (1994) 552-554
17. Wortmann G.W., Aronson N.E., Miller R.S., Blazes D., and Oster C.N. Cutaneous leishmaniasis following local trauma: a clinical pearl. Clin Infect Dis 31 (2000) 199-201
18. Al-Qurashi A.R., Ghandour A.M., Osman M., and Al-Juma M. Dissemination in cutaneous leishmaniasis due to Leishmania major in different ethnic groups in Saudi Arabia. Int J Dermatol 39 (2000) 832-836
19. Turetz M.L., Machado P.R., Ko A.I., et al. Disseminated leishmaniasis: a new and emerging form of leishmaniasis observed in northeastern Brazil. J Infect Dis 186 (2002) 1829-1834
20. Schraner C., Hasse B., Hasse U., et al. Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1. Clin Infect Dis 40 (2005) e120-e124
21. Silveira F.T., Lainson R., and Corbett C.E.P. Clinical and immunopathological spectrum of American cutaneous leishmaniasis with special reference to the disease in Amazonian Brazil-a review. Mem Inst Oswaldo Cruz 99 (2004) 239-251
22. Murray H.W., Berman J.D., Davies C.R., and Saravia N.G. Advances in leishmaniasis. Lancet 366 (2005) 1561-1577
23. Ahluwalia S., Lawn S.D., Kanagalingam J., Grant H., and Lockwood D.N.J. Mucocutaneous leishmaniasis: an imported infection among travellers to central and South America. BMJ 329 (2004) 842-844
24. Lawn S.D., Whetham J., Chodini P.L., et al. New world mucosal and cutaneous leishmaniasis: an emerging health problem among British travellers. QJM 97 (2004) 781-788
25. Couppie P., Clyti E., Sobesky M., et al. Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIV-infected patients in French Guiana. Br J Dermatol 151 (2004) 1165-1171
26. Pintado V., and Lopez-Velez R. HIV-associated visceral leishmaniasis. Clin Microbiol Infect 7 (2001) 291-300
27. Motta A.C., Arruda D., Souza C.S., and Foss N.T. Disseminated mucocutaneous leishmaniasis resulting from chronic use of corticosteroid. Int J Dermatol 42 (2003) 703-706
28. Gontijo C.M., Pacheco R.S., Orefice F., Lasmar E., Silva E.S., and Melo M.N. Concurrent cutaneous, visceral and ocular leishmaniasis caused by Leishmania (Viannia) braziliensis in a kidney transplant patient. Mem Inst Oswaldo Cruz 97 (2002) 751-753
29. Ben Salah, Zakraoui H., Zaatour A., et al. A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am J Trop Med Hyg 53 (1995) 162-166
30. Asilian A., Jalayer T., Whitworth J.A., Ghasemi R.L., Nilforooshzadeh M., and Olliaro P. A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for the treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg 53 (1995) 648-651
31. Dowlati Y. Cutaneous leishmaniasis: clinical aspects. Clin Dermatol 14 (1996) 425-431
32. Herwaldt B., Arana B., and Navin T. The natural history of cutaneous leishmaniasis in Guatemala. J Infect Dis 165 (1992) 518-527
33. Teklemariam S., Hiwot A.G., Frommel D., Miko T.L., Ganlov G., and Bryceson A. Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica. Trans R Soc Trop Med Hyg 88 (1994) 334-339
34. Siriwardena H.V., Udagedara C.U., and Karunaweera N.D. Clinical features, risk factors and efficacy of cryotherapy in cutaneous leishmaniasis in Sri Lanka. Ceylon Med J 48 (2003) 10-12
35. Ben Said M., Guerbouj S., Saghrouni F., Fathallah-Mili A., and Guizani I. Occurrence of Leishmania infantum cutaneous leishmaniasis in central Tunisia. Trans R Soc Trop Med Hyg 100 (2006) 521-526
36. Ponce C., Ponce E., Morrison A., et al. Leishmania donovani chagasi: new clinical variant of cutaneous leishmaniasis in Honduras. Lancet 337 (1991) 67-70
37. Belli A., Garcia D., Palacios X., et al. Widespread atypical cutaneous Leishmaniasis caused by Leishmania (L.) chagasi in Nicaragua. Am J Trop Med Hyg 61 (1999) 380-385
38. Magill A.J. Cutaneous leishmaniasis in the returning traveler. Infect Dis Clin North Am 19 (2005) 241-266
39. Bailey M.S., Green A.D., Ellis C.J., et al. Clinical guidelines for the management of cutaneous leishmaniasis in British military personnel. J R Army Med Corps 151 (2005) 73-80
40. Herwaldt B.L. Leishmaniasis. Lancet 354 (1999) 1191-1199
41. Ramirez J.R., Agudelo S., Muskus C., et al. Diagnosis of cutaneous leishmaniasis in Colombia: the sampling site within lesions influences the sensitivity of parasitologic diagnosis. J Clin Microbiol 38 (2000) 3768-3773
42. Dar N.R., and Khurshid T. Comparison of skin smears and biopsy specimens for demonstration of Leishmania tropica bodies in cutaneous leishmaniasis. J Coll Physicians Surg Pak 15 (2005) 765-767
43. Laskay T., Miko T.L., Negesse Y., Solbach W., Rollingoff M., and Frommel D. Detection of cutaneous Leishmania infection in paraffin-embedded skin biopsies using the polymerase chain reaction. Trans R Soc Trop Med Hyg 89 (1995) 273-275
44. Bensoussan E., Nasereddin A., Jonas F., Schnur L.F., and Jaffe C.L. Comparison of PCR assays for diagnosis of cutaneous leishmaniasis. J Clin Microbiol 44 (2006) 1435-1459
45. Wortmann G., Hochberg L., Houng H.H., et al. Rapid identification of Leishmania complexes by a real-time PCR assay. Am J Trop Med Hyg 73 (2005) 999-1004
46. Allahverdiyev A.M., Uzun S., Bagirova M., Durdu M., and Memisoglu H.R. A sensitive new microculture method for diagnosis of cutaneous leishmaniasis. Am J Trop Med Hyg 70 (2004) 294-297
47. Chargui N., Bastien P., Kallel K., et al. Usefulness of PCR in the diagnosis of cutaneous leishmaniasis in Tunisia. Trans R Soc Trop Med Hyg 99 (2005) 762-768
48. Ihalamulla R.L., Rajapaksa U.S., and Karunaweera N.D. Microculture for the isolation of Leishmania, modified to increase efficacy: a follow-up to a previous study. Ann Trop Med Parasitol 100 (2006) 87-89
49. Al-Jaser M.H. Treatment trends of cutaneous leishmaniasis in Saudi Arabia. Saudi Med J 26 (2005) 1220-1224
50. Blum J., Desjeux P., Schwartz E., Beck B., and Hatz C. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother 53 (2004) 158-166
51. Arana B.A., Mendoza C.E., Rizzo N.R., and Kroeger A. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg 65 (2001) 466-470
52. Armijos R.X., Weigel M.M., Calvopina M., Mancheno M., and Rodriguez R. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Acta Trop 91 (2004) 153-160
53. Faghihi G., and Tavakoli-kia R. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate. Clin Exp Dermatol 28 (2003) 13-16
54. Iraji F., and Sadeghinia A. Efficacy of paromomycin ointment in the treatment of cutaneous leishmaniasis: results of a double-blind, randomized trial in Isfahan. Iran Ann Trop Med Parasitol 99 (2005) 3-9
55. Soto J.M., Toledo J.T., Gutierrez P., et al. Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. Am J Trop Med Hyg 66 (2002) 147-151
56. Mujtaba G., and Khalid M. Weekly vs. fortnightly intralesional meglumine antimoniate in cutaneous leishmaniasis. Int J Dermatol 38 (1999) 607-609
57. Asilian A., Sadeghinia A., Faghihi G., and Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol 43 (2004) 281-283
58. Alrajhi A.A., Ibrahim E.A., De Vol E.B., Khairat M., Faris R.M., and Maguire J.H. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 346 (2002) 891-895
59. Morizot G., Delgiudice P., Caumes E., et al. Healing of Old World Cutaneous Leishmanasis in travellers treated with fluconazole: Drug effect or spontaneous evolution?. Am J Trop Med Hyg 76 (2007) 48-52
60. Willard R.J., Jeffcoat A.M., Benson P.M., and Walsh D.S. Cutaneous leishmaniasis in soldiers from Fort Campbell, Kentucky returning from Operation Iraqi Freedom highlights diagnostic and therapeutic options. J Am Acad Dermatol 52 (2005) 977-987
61. Saenz R.E., Paz H., and Berman J.D. Efficacy of ketoconazole against Leishmania braziliensis and panamensis cutaneous leishmaniasis. Am J Med 89 (1990) 147-155
62. Navin T.R., Arana B.A., Arana F.E., Berman J.D., and Chajon J.F. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 165 (1992) 528-534
63. Salmanpour R., Handjani F., and Nouhpisheh M.K. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis. J Dermatolog Treat 12 (2001) 159-162
64. Momeni A.Z., Jalayer T., Emamjomeh M., et al. Treatment of cutaneous leishmaniasis with itraconazole: randomised double-blind study. Arch Dermatol 132 (1996) 784-786
65. Nassiri-Kashani M., Firooz A., Khamesipour A., et al. A randomized, double-blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis. J Eur Acad Dermatol Venereol 19 (2005) 80-83
66. Soto-Mancipe J., Grogl M., and Berman J.D. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin Infect Dis 16 (1993) 417-425
67. Soto J., Arana B.A., Toledo J., et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 38 (2004) 1266-1272
68. Herwaldt B.L., and Berman J.D. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 46 (1992) 296-306
69. Aronson N.E., Wortmann G.W., Johnson S.C., et al. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent US military experience. Clin Infect Dis 27 (1998) 1457-1464
70. Wortmann G., Miller R.S., Oster C., Jackson J., and Aronson N. A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clin Infect Dis 35 (2002) 261-267
71. Medicines and Healthcare products Regulatory Agency. Drug Alert - Pentostam Injection.MDR 47-03/66 dated 11 April 2006.
72. Croft S.L., Sundar S., and Fairlamb A.H. Drug resistance in leishmaniasis. Clin Microbiol Rev 19 (2006) 111-126
73. Roussel M., Nacher M., Fremont G., et al. Comparison between one and two injections of pentamidine isethionate, at 7 mg/kg in each injection, in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol 100 (2006) 307-314
74. Seaton R.A., Morrsion J., Man I., Watson J., and Nathwani D. Out-patient parenteral antimicrobial therapy-a viable option for the management of cutaneous leishmaniasis. Q J Med 92 (1999) 659-667
75. Lawn S.D., Armstrong M., Chilton D., and Whitty C.J. Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travellers. Trans R Soc Trop Med Hyg 100 (2006) 264-269
76. Lightburn E., Morand J.J., Meynard J.B., et al. Management of American cutaneous leishmaniasis: outcome of 326 cases treated with high-dose pentamidine isethionate. Med Trop (Mars) 63 (2003) 35-44
77. Andersen E.M., Cruz-Saldarriaga M., Llanos-Cuentas A., et al. Comparison of meglumine antimoniate and pentamidine for Peruvian cutaneous leishmaniasis. Am J Trop Med Hyg 72 (2005) 133-137
78. Brown M., Noursadeghi M., Boyle J., and Davidson R.N. Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis. Br J Dermatol 153 (2005) 203-205
79. Wortmann G.W., Fraser S.L., Aronson N.E., et al. Failure of amphotericin B lipid complex in the treatment of cutaneous leishmaniasis. Clin Infect Dis 26 (1998) 1006-1007
80. Requena J.M., Iborra S., Carrion J., Alonso C., and Soto M. Recent advances in vaccines for leishmaniasis. Expert Opin Biol Ther 4 (2004) 1505-1517
81. Tuck J.J.H., Green A.D., and Roberts K.I. A malaria outbreak following a British military deployment to Sierra Leone. J Infect 47 (2003) 225-230